Since utrophin expression is unabated in DMD patients, our small molecule approach to upregulate utrophin should circumvent many of the hurdles associated with delivery, toxicity and immune reaction of conventional DMD gene therapy (e.g. immune reactions against dystrophin itself or the capsid components of the viral vectors used for gene therapy). This evidence concerns the gene UTRN and Duchenne muscular dystrophy.